Sept 8 (Reuters) - Sept 8 (Reuters) - Novo Nordisk A/S:
* New data from a phase 3 study confirms clinical benefits of once-daily
liraglutide in the management of type 2 diabetes
* Says difference between groups receiving liraglutide and group treated with
metformin, rosiglitazone alone was statistically significant
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
tf.TFN-Europe_newsdesk@thomsonreuters.com cmr COPYRIGHT Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
* New data from a phase 3 study confirms clinical benefits of once-daily
liraglutide in the management of type 2 diabetes
* Says difference between groups receiving liraglutide and group treated with
metformin, rosiglitazone alone was statistically significant
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
tf.TFN-Europe_newsdesk@thomsonreuters.com cmr COPYRIGHT Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
© 2008 AFX News
